Sentynl completes asset transfer of CUTX-101 Copper Histidinate product candidate for treatment of…
A rolling submission of the CUTX-101 New Drug Application (NDA) to the FDA is ongoing, with expected completion in 2024
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Sentynl Therapeutics
Copper Histidinate data to be presented at 2022 American College of Medical Genetics Annual Clinical…
The previously reported results are from an efficacy and safety analysis of data integrated from two completed pivotal studies in…
Sentynl Therapeutics and BridgeBio Pharma announce asset purchase agreement for Nulibry
Under the terms of the agreement, Sentynl will acquire global rights to Nulibry, and will be responsible for its ongoing…